Synchron Pauses Trials of Its Next-Generation Stentrode Over a Lead Problem, Says Safety Is Not the Issue
Synchron has paused trials of its second-generation brain-computer interface after reported problems with the lead connecting its vessel-based electrodes to the implant electronics. The company says safety is not the issue. It is cutting New York jobs and plans to bring lead design and manufacturing in-house.
Targeting MET Resistance: Savolitinib Plus Osimertinib Extends Survival Over Chemotherapy in Phase 3 SAFFRON Trial
When EGFR-mutated lung cancer stops responding to Tagrisso, the MET pathway is often to blame. A phase 3 trial found that adding the MET inhibitor savolitinib to Tagrisso helped patients live longer than chemotherapy did, but serious side effects were more common.